Plant-derived Exosome-like Nanovesicles in Biomedical Applications
Progress in Biochemistry and Biophysics · 01.06.2026 · 53 (6) · 1609-1621
DOI: 10.3724/j.pibb.2026.0201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Progress in Biochemistry and Biophysics, online erschienen am 10.07.2026. Verfasst von Xu LIU und 6 weiteren Autor:innen. Die Arbeit nennt 76 Literaturangaben.
Abstract (Originalsprache)
Plant-derived exosome-like nanovesicles (PELNs), characterized by a natural lipid bilayer membrane, have rapidly emerged as a prominent research frontier in medicine owing to their unique biological properties and robust therapeutic potential. This review comprehensively examines the biological profiles, mechanistic functions, and recent engineering advancements of PELNs. In terms of composition, PELNs are uniquely enriched in plant-specific glycolipids, phosphatidylserine, secondary metabolites, and highly stable 2'-O-methylated miRNAs. This distinct molecular makeup endows them with exceptional biocompatibility, negligible immunogenicity, and the capacity for cross-species molecular communication. Mechanistically, PELNs demonstrate profound anti-inflammatory efficacy by suppressing the NF-κB and NLRP3 inflammasome pathways. They also serve as potent immune modulators, driving macrophage M1/M2 polarization and regulating T cell activity. Additionally, PELNs exhibit promising antitumor capabilities, targeting malignancies via reactive oxygen species (ROS) induction, TRAIL pathway activation, and tumor microenvironment remodeling. Crucially, the plant miRNAs encapsulated within PELNs remain highly stable in the gastrointestinal tract, allowing them to selectively alter gene expression in specific gut microbiota communities. This interaction deeply influences host immunity and metabolism, highlighting the vital role in cross-species regulation. Advancements in bioengineering have further expanded the clinical utility of PELNs. Targeted delivery efficiency can be significantly amplified via surface functionalization (e.g., folate and RGD sequences) and state-of-the-art drug loading technologies such as sonication and electroporation. Consequently, engineered PELNs surpass traditional synthetic nanocarriers in penetrating natural physiological barriers, particularly for oral and transdermal drug administration. Despite these advantages, clinical translation is currently hindered by the lack of standardized isolation protocols, challenges in scalable manufacturing, and the need for robust quality control frameworks. Looking forward, the integration of multi-omics approaches and AI-driven “molecular fingerprinting”—coupled with the design of synthetic biomimetic vesicles—will be instrumental in overcoming these bottlenecks, ultimately establishing PELNs as a next-generation platform for precision medicine and targeted nanotherapeutic delivery.
Zitieren
APA
LIU, X., LIU, S., MA, J., MOU, Y., SHI, T., HUANG, S., & SONG, T. (2026). Plant-derived Exosome-like Nanovesicles in Biomedical Applications. Progress in Biochemistry and Biophysics, 53(6), 1609-1621. https://doi.org/10.3724/j.pibb.2026.0201
Vancouver
LIU X, LIU S, MA J, MOU Y, SHI T, HUANG S, et al. Plant-derived Exosome-like Nanovesicles in Biomedical Applications. Progress in Biochemistry and Biophysics. 2026;53(6):1609-1621. doi:10.3724/j.pibb.2026.0201
BibTeX
@article{LIU2026,
author = {LIU, Xu and LIU, Si-Rui and MA, Jia-Yu and MOU, Yu-Ting and SHI, Ting-Yu and HUANG, Sheng and SONG, Tian-Li},
title = {Plant-derived Exosome-like Nanovesicles in Biomedical Applications},
journal = {Progress in Biochemistry and Biophysics},
year = {2026},
volume = {53},
number = {6},
pages = {1609--1621},
doi = {10.3724/j.pibb.2026.0201}
}
EUVIMED